Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies
This is a pilot study to evaluate the use feasibility of the iThermonitor, a continuous temperature monitoring device, as a clinical support and patient self-management tool in the management of pediatrics patients on myelosuppressive therapies for acute leukemia and other childhood cancers.
Study Start Date
Estimated Completion Date
- Device: iThermonitor
- Nursing: Hematology/Oncology,Pediatrics
- Pediatrics: Pediatric Heme/Oncology
- Family Medicine: Peds Family Medicine
- Oncology: Leukemia/Lymphoma,Peds Heme/Oncology,Pharmacology/Therapy
- Physician Assistant: Hematology/Oncology,Pediatrics
- Practice Management: Technology
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Lymphoma, Non-Hodgkin
Massachusetts General Hospital -- 14-485
Massachusetts General Hospital
- Dyad consists of a pediatric patient aged 2-17 years undergoing myelosuppressive therapies for acute leukemias and other childhood cancers.
- Dyad also includes a caregiver, ? 18 years of age that is willing to participate in the study.
- Ability of caregiver or patient (if old enough) to read and speak English.
- If applicable, willingness of the patient to shave axillary (armpit) hair.
- Caregiver (parent or legal guardian) must give informed consent for dyad participation.
- Patient has a history of allergy to hydrogel dressing or ongoing skin diseases
- Patients with ongoing febrile illness or documented infectious disease.
2 Years to 17 Years
Accepts Healthy Volunteers
Study Locations and Contact Information (1)
|Massachusetts General Hospital - Boston, Massachusetts||2.8 miles||Suzanne Rossov||617-643-6395||Srossov@PARTNERS.ORG|